Savara (NASDAQ:SVRA) Given New $11.00 Price Target at Guggenheim

Key Points

• Guggenheim raised its price target for Savara (NASDAQ:SVRA) from $8.00 to $11.00, indicating a potential upside of 185.71% from the current price and maintaining a "buy" rating on the stock.
• Overall, Savara has a consensus rating of "Moderate Buy" with an average target price of $7.50, as assessed by multiple analysts.
• Institutional investors have significantly increased their holdings in Savara, with over 87.93% of the stock now owned by institutional investors and hedge funds.

Savara (NASDAQ:SVRA - Get Free Report) had its price objective upped by equities researchers at Guggenheim from $8.00 to $11.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Guggenheim's price objective points to a potential upside of 185.71% from the company's current price.

Several other equities analysts have also recently commented on the stock. Evercore ISI lowered their target price on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research note on Wednesday, May 28th. Oppenheimer lifted their price objective on shares of Savara from $6.00 to $8.00 and gave the stock an "outperform" rating in a research note on Monday. HC Wainwright lifted their price objective on shares of Savara from $5.00 to $8.00 and gave the stock a "buy" rating in a research note on Wednesday, September 3rd. Finally, Wells Fargo & Company lowered their price objective on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 28th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $7.50.

Savara Trading Up 3.5%

Shares of NASDAQ:SVRA opened at $3.85 on Tuesday. The company has a market cap of $665.43 million, a PE ratio of -7.70 and a beta of 0.56. The company's 50-day moving average price is $2.75 and its 200 day moving average price is $2.72. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $4.70. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Sell-side analysts anticipate that Savara will post -0.45 earnings per share for the current year.

Insider Activity at Savara

In other news, Director Richard J. Hawkins bought 48,225 shares of the firm's stock in a transaction on Friday, June 20th. The stock was bought at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the completion of the acquisition, the director directly owned 115,466 shares in the company, valued at $235,550.64. This represents a 71.72% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 5.13% of the stock is currently owned by insiders.

Institutional Trading of Savara

Several institutional investors have recently made changes to their positions in the stock. Bain Capital Life Sciences Investors LLC lifted its stake in Savara by 20.8% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company's stock valued at $48,754,000 after acquiring an additional 3,035,164 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in Savara by 32.4% in the first quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company's stock valued at $31,751,000 after acquiring an additional 2,801,922 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Savara by 2.1% in the first quarter. Vestal Point Capital LP now owns 11,000,000 shares of the company's stock valued at $30,470,000 after purchasing an additional 225,000 shares during the period. VR Adviser LLC raised its position in shares of Savara by 172.7% in the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company's stock valued at $20,256,000 after purchasing an additional 5,626,624 shares during the period. Finally, Nantahala Capital Management LLC raised its position in shares of Savara by 3.1% in the second quarter. Nantahala Capital Management LLC now owns 8,325,375 shares of the company's stock valued at $18,982,000 after purchasing an additional 250,000 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.